Nektar Therapeutics (Nasdaq:NKTR - News) today reported results announced by Pfizer Inc from two ongoing studies that showed adults with type 1 or type 2 diabetes treated with Exubera® (insulin human (rDNA origin)) Inhalation Powder experienced sustained blood sugar control over a two-year period and gained about half as much weight as those taking injected insulin. These data were presented today at the 66th Annual Scientific Sessions of the American Diabetes Association.
